拓扑替康在宫颈癌治疗中的抗癌效应

Anti-cancer Effect of Topotecan in the Treatment for Cervical Cancer

[目的]探讨DNA拓扑异构酶Ⅰ抑制剂——拓扑替康在宫颈癌治疗中的抗癌活性。[方法]将60例病理证实宫颈癌Ⅰb2期～Ⅳb期患者分为动脉化疗组和静脉化疗组,分别给予拓扑替康1.25mg/(m2·d),化疗15天后根据病理损伤程度进行疗效评定。[结果]60例病理总有效率为68%(41/60),动脉化疗组有效率为81%(26/32),静脉化疗组有效率为54%(15/28),两组间差异有显著性(P<0.05)。[结论]拓扑替康是治疗中、晚期宫颈癌有效的药物,动脉化疗疗效优于静脉化疗。

[Purpose] To investigate the anti-cancer activity of topoisomerase ] inhibitor（topotecan） in the treatment for cervical cancer. [Methods]Sixty pathologically proved cervical cancer patients stage Ⅰ h2-Ⅳh were divided into arterial chemotherapy group and venous chemotherapy group, Two groups were both given topotecan 1.25mg/（m^2. d） for 15 days. Chemotherapeutic efficacy was evaluated by pathological damage degree. [ Results ] Pathology response rate in 60 cases was 68%（41/60）, with 81%（26/32） in arterial chemotherapy group, 54% （15/28） in venous chemotherapy group. There was significant difference between 2 groups （P〈0.05）. [Conclusion] Topotecan is an effective agent for the treatment of advance cervical cancer, and the arterial chemotherapy is superior to venous chemotherapy.